Pierre Fabre, a French pharmaceutical company, has agreed to acquire several assets from Igenica Biotherapeutics, a Burlingame, California-based biopharmaceutical company developing immunotherapies and antibody drug conjugates. The agreement includes immunotherapies targeting immune checkpoints that may reverse the resistance to existing immunotherapies. The most advanced asset is currently in preclinical development and is expected to be administered to patients in the coming two to three years. The agreement also comprises a series of early-discovery targets.

Under the agreement, Pierre Fabre has acquired the full property of the assets. The financial terms of the agreement were not disclosed.

Source: Pierre Fabre